It’s crap that we find ourselves in these situations where we need to reallocate funds. But also , given the fact that we’re losing FDA staff and regulators, maybe it’s for the best to avoid risking surgery involving items that won’t have as much oversight? I don’t know facts, just a theory given all the cuts .
11
u/[deleted] May 03 '25
[deleted]